Voluntary nationwide recall: Potassium (Bluepoint – June)

Aug. 2024Pharmacy Updates

BluePoint Laboratories is recalling 21 batches of Potassium Chloride Extended-Release Capsules, USP (750 mg) 10 mEq K. Potassium Chloride is used for the treatment of low potassium.

This drug is being recalled because the product failed to dissolve in the body. This may cause high potassium levels, which can result in irregular heartbeat that can lead to cardiac arrest.

As of the date of BluePoint’s recall announcement, June 25, 2024, there have been no reports of adverse events related to this recall. Consult your health care provider before you stop using this product. To see if your medication was recalled, contact your doctor or pharmacy where you received the medication or visit the FDA website below.

To learn more about this recall, you can take one or more of the steps below.

  • Talk to your doctor or pharmacist.
  • Call Sedgwick at 1-855-695-8564. TTY users should call 711. Help is available Monday through Friday from 8 a.m. to 5 p.m. EST.
  • Visit the FDA website.

Recent Announcements

Voluntary nationwide recall: True Metrix (Trividia – May)

Trividia Health is recalling all True Metrix Blood Glucose Systems for an issue with the software design of the E-5 Error Code and instructions for the user in the “Messages” section of the Owner’s Booklet/System instructions for use and online labeling and help guides.
May 2026Pharmacy Updates

Community Care Behavioral Health is excited to announce this free upcoming web-based training opportunity:

A growing body of U.S. and international research demonstrates that the rapid legalization and commercialization of gambling—including online casinos and mobile sports betting platforms—are associated with significant and escalating gambling related harm. Although Pennsylvania specific prevalence data remain limited, available evidence is increasingly concerning, with gambling disorder linked to alarmingly high rates of suicide, psychiatric comorbidity, and social and financial harm. Drawing on lessons from the tobacco and opioid crises, this presentation will examine how delayed recognition and regulation can amplify population level harm, underscoring the need for earlier screening, prevention, and policy engagement. Participants will gain practical guidance on identifying patients at elevated risk, implementing evidence informed screening and diagnostic strategies, and applying current treatment approaches across the lifespan.
May 2026Education/Webinars

Bridging Smiles and Systems: Collaborative Care for Children with Chronic Conditions

Please join us for a live, CME-accredited and CEU-accredited webinar on May 13 from noon to 1p.m., that will explore the critical connection between oral health and pediatric chronic conditions such as diabetes, asthma, congenital heart disease, and ADHD.
Apr. 2026Education/Webinars